Tissue-Link develops a pipeline of novel Medical Device solutions for unmet needs inside and outside the surgical field.
Our first candidate is a unique Hemostat for Severe Arterial Bleedings (TL101).
A pioneering breakthrough in protein cross-binding has led to the development of a unique, patented platform technology. The technology allows safe use of highly efficacious biomolecules and has wide-ranging applications in human health.
The first candidate from this technology is a revolutionary Hemostatic Medical Device for managing severe bleeding – the first and only product globally that is using tissue factor for both safe and effective for treatment of severe arterial bleeding.
Vision statement:
To become market leader within the global market in hemostatic technology by introducing a new category of products capable of stopping arterial bleeding, thereby setting new standards in trauma care and surgery.
Market Position
Tissue-Link operates in a market with significant demand for efficient hemostatic solutions, particularly for arterial and severe venous bleeding. With no major technological advancements in the field over the past 25 years, Tissue-Link’s innovative products address a critical gap. The company’s solutions are poised to reduce the high costs associated with in-hospital bleedings from surgeries and improve survival rates in trauma and combat situations.
Market Size and Growth
The global hemostat market is projected to double from USD 5.08 billion in 2023 to more than USD 10 billion by 2032, at a compounded annual growth rate (CAGR) level of 8% during the period. North America contributed the highest revenue share of 34% in 2022, driven by advanced healthcare infrastructure, significant research and development activities, and the presence of leading medical device manufacturers. The Asia-Pacific region is expected to witness the fastest growth, attributed to expanding healthcare facilities and increasing surgical procedures in emerging economies.
